Dendreon (DNDN) Takes a Downer as ZYTIGA Makes News
Tweet
Share
E-mail
Get Alerts DNDN Hot Sheet
Join SI Premium – FREE
After a speculation-fueled run-up so far this week, Dendreon Corp. (Nasdaq: DNDN) is weaker Friday as news on competing drug ZYTIGA takes the spotlight.
Today, Johnson & Johnson's (NYSE: JNJ) Janssen-Cilag unit announced that it submitted a type II variation to the European Medicines Agency (EMA) for ZYTIGA. In addition, they submitted a supplemental New Drug Application (sNDA) to the U.S. FDA.
Shares of DNDN are down 1 percent early Friday, but still up 19 percent on the week. Most of the upside can be attributed to unconfirmed takeover speculation and a new Buy rating.
Today, Johnson & Johnson's (NYSE: JNJ) Janssen-Cilag unit announced that it submitted a type II variation to the European Medicines Agency (EMA) for ZYTIGA. In addition, they submitted a supplemental New Drug Application (sNDA) to the U.S. FDA.
Shares of DNDN are down 1 percent early Friday, but still up 19 percent on the week. Most of the upside can be attributed to unconfirmed takeover speculation and a new Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Musalem: strong growth and investment influencing bond market - CNBC
- Boeing, RTX $4.5b Aircraft Sale to Qatar Gets Tentative Approval
- Bessent: nothing magic about $40 trillion debt number
Create E-mail Alert Related Categories
Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
